INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08887.0042	Serial No.	09/874,991
Applicant	James J. MOND et al.		
Filing Date	June 7, 2001	Group:	1645

		U.S. PATEN	T DOCUMENTS			
Examiner P Private	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
MAN	6,239,116 B1	May 29, 2001	Krieg et al.	514	44	
01 0 10	6,214,806 B1	April 10, 2001	Krieg et al.	514	44	
/1.8/N /	6,218,371 B1	April 17, 2001	Krieg et al.	514	44	
ATENT & TRADE						
DEOENT	-5	, i			·	
RECEIVE	- P					
OCT 0 3 200	1					
ECH CENTER 160	0/2900					·

FOREIGN PATENT DOCUMENTS									
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No			
- 1									
			· · · · · · ·						
-									

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	

	unication to applicant.
throug	f reference considered, whether or not citation is in conformance with MPEP 609; draw line h citation if not in conformance and not considered. Include copy of this form with next

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011 RECEIVED

		101E	\		1 11-	
Atty. Docket No.	07787.0042	1	Appln. No.	09/874,991	MA	R 1 3 2002
Applicant	James J. MOND et al	MAR 1 1 2002	3		7501.05	NTED 4000/2000
Filing Date	June 7, 2001	THE TRADEMARK	Group:	164 5	TECH CE	NTER 1600/2900
			T DOCUMENTS	<u> </u>	<u> </u>	
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
Mu	6,001,989	12/14/99	Jennings et a	1.		
M	5,708,154	01/13/98	Smith et al.		3	
					.'\	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
					MAR	VV

FOREIGN PATENT DOCUMENTS									
	Document Number	Publication Date	Country	Class	Sub Class	Translati n Yes or No			
	EP 0 818 202 A1	01/14/98	EP						
		1							
77									

 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
 Copy of European Patent Office search report dated December 2, 2002.

Examiner	1	1711	Mr	nnife	(U)	Date Considere	ed	8/3	31/04	L	
*Examiner:	th	itial if re	eference o	considered,	whether or	not citation is in co not considered.	onforma nclude	ance wi	th MPEP f this form	P 609; draw n with next	line
Form PTO 1	449				Patent an	d Trademark C	Office -	U.S.	Departi	ment of C	ommerce

9	SEP 0 7 2001	ON DISCLOSURE CITATION	OMB No. 651-	PEC C
Atty. Docket No.	07787.0042	Appln. No. 09/874,991	TER	
Applicant	James J. MOND et al.	٠	160	200
Filing Date	June 7, 2001	Group: Unassigned 164	5 <u> </u> 28	

		U.S. PATEN	T DOCUMENTS			
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
My	6,194,388 B1	02/27/01	Krieg et al.			
1009	6,008,200	12/28/99	Krieg			
M	5,935,527	08/10/99	Andrus et al.			
	5,747,024	05/05/98	Grabstein et al.			
111/1	5,478,556	12/26/95	Elliott et al.			

FOREIGN PATENT DOCUMENTS									
	Document Number	Publication Date	Country	Class	Sub Class	Translati n Yes or N			
MM	WO 99/61056 /	12/02/99	PCT	1					
m	WO 99/51259	10/14/99	PCT						
m	WO 98/40100	09/17/98	PCT						
M	WO 98/37919 /	09/03/98	PCT						
m	WO 98/18810 ´	,05/07/98	PCT						
M	WO 96/02555 A1	02/01/96	PCT						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
M	Amano, M. et al., "Immunofluorescence-Digital Image Processing System for the Quantitation of Secreted Immunoglobulin by Single Cells," <i>Journal of Immunological Methods</i> , 144, pp. 127-140 (1991).		
Barry, M. E. et al., "Role of Endogenous Endonucleases and Tissue Site in Transfection and Cp Mediated Immune Activation after Naked DNA Injection," <i>Human Gene Therapy</i> , 10, pp. 2461-2480 (1999).			
Bauer, M. et al., "DNA Activates Human Immune Cells Through a CpG Sequence-Dependence," Immunology, 97, pp. 699-705 (1999).			
Behboudi, S. et al., "The Effects of DNA Containing CpG Motif on Dendritic Cells, <i>Immunolog</i> pp. 361-366 (2000).			
Bendigs, S. et al., "CpG-Oligodeoxynucleotides Co-Stimulate Primary T Cells in the Absence Antigen-Presenting Cells," Eur. J. Immunol., 29, pp. 1209-1218 (1999).			
m	Bohle, B. et al., "Oligodeoxynucleotides Containing CpG Motifs Induce IL-12, IL-18 and IFN-γ Production in Cells from Allergic Individuals and Inhibit IgE Synthesis in Vitro," <i>Eur. J. Immunol.</i> , 29, pp. 2344-2353 (1999).		

MM Munsifield 8/31/04 Page 1 of 8

•	SEP 0 7 2001 SEP ORMATION DI	SCLOSURE CITATION	OMB N 0651-011
Atty. Docket No.	0778 CB49EMAPP	Appln. No. 09/874,991	
Applicant	James J. MOND et al.	Appln. No. 09/874,991	
Filing Date	June 7, 2001	Group: Unassigned 164	45 50 01 T
	OTHER DOCUMENTS (Including Au	ıthor, Title, Date, Pertinent Pages	s, Etc.)
M	Broide, D. et al., "DNA-Based Immur 456 (1999).	nization for Asthma," Int. Arch Allerg	<i>y Immunol.</i> , 118, pp. 453-
m	Brown, W. C. et al., "Modulation of H Immunology and Immunopathology,"		al DNA," Veterinary
M	Carpentier, A. F. et al., "Oligodeoxyn Neuroblastoma in Mice," Cancer Res		Can Induce Rejection of a
m	Chelvarajan, R. L. et al. CpG Oligode B Cells to Stimulation with the Thymu Immuol., 29, pp. 2808-2818 (1999).		
My	Chiaramonte, M. G. et al., "CpG Oligo Mediated Schistosome Egg-Induced of Immunology, 162:2, pp. 973-985 (2014)	Pathology by an IL-12-Independen	
m	Cho, H. et al., "Immunostimulatory DNA-Based Vaccines Induce Cytotoxic Lymphocyte Activity by a T-Helper Cell-Independent Mechansim," <i>Nature Biotechnology</i> , 18, pp. 509-514 (2000).		
mi-	Chu, R. S. et al., "CpG DNA Switches on Th1 Immunity and Modulates Antigen-Presenting Cell Function," <i>Immunobiology of Bacterial CpG</i> -DNA, pp. 199-210, Springer, Edited by H. Wagner (2000)		
M	Chu, R. S. et al., CpG Oligodeoxynucleotides Act as Adjuvants for Pneumococcal Polysaccharide- Protein Conjugate Vaccines and Enhance Antipolysaccharide Immunoglobulin G2a (IgG2a) and IgG3 Antibodies," <i>Infection and Immunity</i> , pp. 1450-1456 (2000).		
M	Czerkinsky, C. C., "A Solid-Phase En of Specific Antibody-Secreting Cells,"	zyme-Linked Immunospot (ELISPO Journal of Immunological Methods	T) Assay for Enumeration 6, 65, pp. 109-121 (1983).
M	Davis, H., " DNA Vaccines for Prophy The Mount Sinai Journal of Medicine		Against Hepatitis B Virus,"
M	Davis, H. L. et al., "DNA Vaccines for	Viral Diseases," Microbes and Infe	oction, 1, pp. 7-21 (1999).
MM -	Davis, H. L. et al., "CpG DNA Overco Orangutans," Vaccine, 18, pp. 1920-		titis B Vaccine in
MM	Davis, H., "Use of CpG DNA for Enha Bacterial CpG-DNA, Springer, Edited		
100	Decker, T. et al., Immunostimulatory Production, and an Immunogenic Phe 3, pp. 999-1006 (2000).		
\mathcal{M}	Deng et al., "The Features of Arthritis Rheumatism, 43, 2, pp. 356-364 (200		II DNA," Arthritis &
My.	Elkins, K. L. et al., "Bacterial DNA Co Protection of Mice Against Lethal Infe 162, 4, pp. 2291-2298 (1999).		

MM Minnfild \$31/04

•	SP 0 7 200 FORMATION DIS	SCLOSURE	CITATION	OMB-No. 0651-0011
Atty. Docket No.	07787.8042	Appln. No.	09/874,991	<u>π</u> π Ω
Applicant	James J. MOND et al.			B 0 1
Filing Date	June 7, 2001	Group:	Unassigned 1645	
	OTHER DOCUMENTS (Including Au	ıthor, Title, Da	ite, Pertinent Pages,	Etc.) 8
M	Feltquate, D. et al., "Effect of CpG Moto Influenza Hemagglutinin-Expressir			
1111	Freidag, B. L. et al., "CpG Oligodeox Mycobacterium Bovis BCG Vaccinati Immunity, pp. 2948-2953 (2000).			
MU	Gilkeson, G. S. et al., "Effects of Back The Journal of Immunology, Vol. 161			y (NZB/NZW)F ₁ Mice ¹ ,
M	Goeckeritz, B. E. et al., "Multivalent C Broader Spectrum of CpG-Containing Counterpartrs, for Stimulation of Proli pp. 1693-1700 (1999).	g Oligodeoxynı	ucleotide Motifs, Includ	ding their Methylated
M	Gursel, M. et al., "Immunoadjuvant Ad 1383 (1999).	ction of Plasmi	id DNA in Liposomes,'	' Vaccine, 17, pp. 1376-
MM	Gurunathan, S. et al., "DNA Vaccines Immunol., 18, pp. 927-974 (2000).	s: Immunology	, Application, and Opt	imization," Annu. Rev.
M	Hacker, S., "Signal Transduction Path CpG-DNA, Springer, Edited by H. Wa			unobiology of Bacterial
MX	Hacker, H. et al., "Cell Type-Specific Activation of Mitogen-Activated Protein Kinases by CpG-DNA Controls Interleukin-12 Release from Antigen-Presenting Cells," <i>The EMBO Journal</i> , Vol. 18, No. 24, pp. 6973-6982 (1999).			
M	Hartmann, G. et al., "Delineation of a Primate Immune Responses In Vitro 1617-1624 (2000).			
M	Hartmann, G. et al., "CpG DNA and L Monocytes," Gene Therapy, 6, pp. 89		tinct Patterns of Active	ation in Human
M	Hartmann, G. et al., "CpG DNA: A Po Dendritic Cells," Proc. Natl. Acad. Sci	tent Signal for i. USA, 96, pp.	Growth, Activation, ar 9305-9310 (1999).	nd Maturation of Human
M	Hartmann, G. et al., "Mechanism and Primary B Cells," The Journal of Imm.	Function of a unology, 164,	Newly Identified CpG 2, pp. 944-952 (2000)	DNA Motif in Human
Mh	Hassett, D. E. et al., "Plasmid DNA Vipp. 175-183 (1999).	accines are Ef	fective in the Absence	of IFNγ," Virology, 263,
M	Heeg, K. et al., "CpG DNA as a Th1 1 121, 2, pp. 87-97 (2000).	Frigger," <i>Intern</i>	ational Archives of All	ergy and Immunology,
M	Heeg, K., "CpG DNA Co-Stimulates A DNA, Springer, Edited by H. Wagner,			ology of Bacterial CpG-
M	Horner, A.A. et al., "Immunostimulato Immunobiology of Bacterial CpG-DNA			

MMinnfull 8/31/04



	SP 0 7 2001 BY ORMAT	ION DISCLOSURE	CITATION	OME	TECHOENTI	RECE Section 1
Atty. Docket No.	07787.90ADE	Appln. No.	09/874,991			22
Applicant	James J. MOND et al.				00	
Filing Date	June 7, 2001	Group:	Unassign ed	1645	366	— P

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
m	Iho, S. et al., "Oligodeoxynucleotides Containing Palindrome Sequences with Internal 5'-CpG-3' Act Directly on Human NK and Activated T Cells to Induce IFN-γ Production In Vitro," <i>The Journal of Immunology</i> , 163, 7, pp. 3642-3652 (1999).
M	Jahn-Schmid, B. et al., "Oligodeoxynucleotides Containing CpG Motifs Modulate the Allergic T _{H2} Response of BALB/c Mice to Bet v 1, the Major Birch Pollen Allergen," <i>J.Allergy Clin. Immunol.</i> , 104, 5, pp. 1015-1023 (1999).
Jones, B. et al., "Reduced In Vitro Production of Interferon-Gamma, Interleukin-4 and Interleukin 12 and Increased Production of Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-Alpha Systemic Lupus Erythematosus. Weak Correlations of Cytokine Production with Disease Activit Autoimmunity, 31, pp. 117-124 (1999).	
m	Jones, T. et al., "Synthetic Oligodeoxynucleotides Containing CpG Motifs Enhance Immunogenicity of a Peptide Malaria Vaccine in Aotus Monkeys," <i>Vaccine</i> , 17, pp. 3065-3071 (1999).
M	Kamstrup, S. et al., "Response of Porcine Peripheral Blood Mononuclear Cells to CpG-Containing Oligodeoxynucleotides," <i>Veterinary Microbiology</i> , 78, pp. 353-362 (2001).
Kim, S. K. et al., "Comparison of the Effect of Different Immunological Adjuvants on the Antiboundary and T-cell Response to Immunization with MUC1-KLH and GD3-KLH Conjugate Cancer Vaccine, 18, pp. 597-603 (2000).	
Kline, J.N., "Effects of CpG DNA on Th1/Th2 Balance in Asthma," Immunobiology of Bacterial CpG-DNA, Springer, Edited by H. Wagner, pp. 211-225 (2000).	
Klinman, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of Immunology, 158, 8, pp. 3635-3639 (1997).	
M	Klinman, D. M. et al., "CpG DNA Augments the Immunogenicity of Plasmid DNA Vaccines," Immunobiology of Bacterial CpG-DNA, Springer, Edited by H. Wagner, pp. 131-141 (2000).
Klinman, D.M. et al., "CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon γ," <i>Proc. Natl. Acad. Sci. USA</i> , 93, pp. 2879 2883 (1996).	
M	Klinman, D.M. et al., "Activation of the Innate Immune System by CpG Oligodeoxynucleotides: Immunoprotective Activity and Safety," <i>Springer Semin Immunopathol.</i> , Edited by E. Raz, 22, pp. 173-183 (2000).
Klinman, D.M., "Therapeutic Applications of CpG-Containing Oligodeoxynucleotides," Antisense Nucleic Acid Drug Development, 8, pp. 181-184 (1998). Klinman, D.M., "Repeated Administration of Synthetic Oligodeoxynucleotides Expressing CpG Motifs Provides Long-Term Protection Against Bacterial Infection," Infection and Immunity, pp. 5658-5663 (1999).	
M	Kobayashi, H. et al., "Immunostimulatory DNA Prepriming: A Novel Approach for Prolonged Th1-Biased Immunity," Cellular Immunology, 198, pp. 69-75 (1999).

NMMnnifull 8/31/04

	(A)	ITION DISCLOSURE CITA	TION	OMB N C C C C C C C C C C C C C C C C C C
Atty. Docket No.	07787.0042 MAN	Appln. No. 09/87	4,991	ğ', Ω
Applicant	James J. MOND et al.			0 20 160
Filing Date	June 7, 2001	Group: Unass	eigned 1645	00 PM

	8 0
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
M	Krieg, A.M. et al., "Mechanisms and Therapeutic Applications of Immune Stimulatory CpG DNA," Pharmacology & Therapeutics, 84, pp. 113-120 (1999).
M	Krieg, A.M., "Direct Immunologic Activities of CpG DNA and Implications for Gene Therapy," <i>The J Gene Med</i> , 1, pp. 56-63 (1999).
M	Krieg, A.M. et al., "Mechanism of Action of CpG DNA," <i>Immunobiology of Bacterial CpG-DNA</i> , Springer, Edited by H. Wagner, pp. 1-21.
m	Krieg, A.M. et al., "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," <i>Nature</i> , 374, pp. 546-549 (1995).
M	Krieg, A.M., "The Role of CpG Motifs in Innate Immunity," Current Opinion in Immunology, 12, 1, pp. 35-43 (2000).
M	Krieg, A.M. et al., "CpG DNA Induces Sustained IL-12 Expression In Vivo and Resistance to Listeria Monocytogenes Challenge," <i>The Journal of Immunology</i> , 161, 5, pp. 2428-2434 (1998).
//W	Krieg, A.M., "CpG DNA: A Novel Immunomodulator," Trends in Microbiology, 7, 2, (1999).
M	Leitner, W.W. et al., "DNA and RNA-based Vaccines: Principles, Progress and Prospects," Vaccine, 18, pp. 765-777 (2000).
m	Liang, H. et al., "Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides," <i>J. Clin. Invest.</i> , 98, 5, pp. 1119-1129 (1996).
m	Liang, H. et al., "Responses of Human B Cells to DNA and Phosphorothioate Oligodeoxynucleotides," <i>Immunobiology of Bacterial CpG-DNA</i> , Springer, Edited by H. Wagner, pp. 227-240 (2000).
M	Lipford, G.B. et al., "Hematopoietic Remodeling Triggered by CpG DNA," Immunobiology of Bacterial CpG-DNA, Springer, Edited H. Wagner, pp. 119-129 (2000).
M	Macfarlane, D.E. et al., "Immunostimulatory CpG-Oligodeoxynucleotides Induce a Factor that Inhibits Macrophage Adhesion," <i>Laboratory and Clinical Medicine</i> , 134, 5, pp. 501-509 (1999).
W	McCluskie, M.J. et al., "CpG DNA as Mucosal Adjuvant," Vaccine, 18, pp. 231-237 (2000).
M	McCluskie, M.J. et al., "Novel Strategies Using DNA for the Induction of Mucosal Immunity," <i>Critical Reviews in Immunology</i> , 19, pp. 303-329 (1999).
4m	McCluskie, M.J. et al., "Cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice," <i>The Journal of Immunology</i> , 161, 9, pp. 4463-4466 (1998).
M	Metzer, W.J. et al., "Oligonucleotide Therapy of Allergic Asthma," Journal of Allergy and Clinical Immunology, 104, 2, pp. 260-266 (1999).
MM	Moss, R.B. et al., "In Vitro Immune Fuction After Vaccination with an Inactivated, gp120-Depleted HIV-1 Antigen with Immunostimulatory Oligodeoxynucleotides," <i>Vaccine</i> , 18, pp. 1081-1087 (2000).

MM Minnifield 8/31/0x Page 5 of 8

(3	SEP U ZOUL EN			ОМВ-Мо. 0651-0011
\ 	TRADE WITH THE PROPERTY OF THE	SCLOSURE	CITATION	유 유 대
Atty. Docket No.	07787.0042	Appln. No.	09/874,991	E F O
Applicant	James J. MOND et al.			田 · · · · · · · · · · · · · · · · · · ·
Filing Date	June 7, 2001	Group:	Unessigned 1645	7 C
	OTHER DOCUMENTS (Including Au	thor, Title, Da	ite, Pertinent Pages, E	tc.) 8 - 111
MM	Oxenius, A. et al., "CpG-Containing C Protective Antiviral Immune Respons 4120-4126 (1999).			
M	Pisetsky, D.S., "The Role of Bacterial CpG-DNA, Springer, Edited by H. Wa			unobiology of Bacterial
M	Sato, Y. et al., "Adjuvant Effect of a 1 Immunology, 197, pp. 145-150 (1999		crolide Antibiotic on DN	A Vaccine," Cellular
MIL	Schwartz, D.A. et al., "Bacterial DNA Minimize Lipopolysaccharide-Induced 12-Dependent Pathway," <i>The Journa</i>	Inflammation	in the Lower Respirator	y Tract Through an IL-
M	Sedgwick, J.D. et al., "A Solid-Phase Antibody-Secreting Cells," Journal of			
M	Shirota et al., "Regulation of T-Helper Coadministration of Antigen and Oligon and Molecular Biology, 22, 2, pp. 176	odeoxynucleot		
MM	Singh, M. et al., "Advances in Vaccino (1999).	e Adjuvants," /	Nature Biotechnology, 1	7, 11, pp. 1075-1081
m	Sparholt, S.H. et al., "Dectection of B Antigens," Clinical and Experimental			Dermatophagoides
M	Sparwasser, T. et al., "Consequences Presenting Cells," <i>Immunobiology of</i> 75 (2000).			
M	Stacey, K.J. et al., "Immunostimulator Major," <i>Infection and Immunity</i> , pp. 33			Against Leishmania
M	Stacey, K.J. et al., "Macrophage Active Bacterial CpG-DNA, Springer, Edited			nmunobiology of
M	Stan, C. A. et al., "CpG Motifs of DNA Class II Molecules on Myocytes," Eur			
M	Subklewe, M. et al., "Presentation of Secreting, T Lymphocytes," Eur. J. In			o CD8, Interferon-γ-
M	Sun, S. et al., "Role of Type I Interferent Immunobiology of Bacterial CpG-DN/			
m	Sur, S. et al., "Long Term Prevention CpG Oligodeoxynucleotides," <i>The Jo</i>			
m	Takeshita, F. et al., "CpG ODN-Media pp. 1967-1976 (2000).	ated Regulation	n of IL-12 p40 Transcrip	tion," Eur. J. Immunol.,
MM.	Takeshita, S. et al., "CpG Oligodeoxy Chemokine mMRNA Expression," Ce			

Page 6 of 8

MMinnfield 8/31/04

OMB No. 0651-0011

	INFORMATION DI	SCLOSURE CITATION	槚	
Atty. Docket No.	07787.0042	Appln. No. 09/874,991	H S III	
Applicant	James J. MOND et al.		N P O	
Filing Date	June 7, 2001	Group: Unassigned 1045		
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	500/29	
MM	Takeshita, F. et al., "Positive and Ne Oligonucleotide-Mediated Regulation 108-116 (2000).	gative Regulatory Elements Contribute to n of Human IL-6 Gene Expression," Eur. J.	CpGS	
M		tory Bacterial DNA Sequences Activate De of CD8 ⁺ T Cells," <i>Immunology</i> , 99, pp. 1-7		
mm		Vabulas, R.M. et al., "CpG-DNA Activates In Vivo T Cell Epitope Presenting Dendritic Cells to Trigger Protective Antiviral Cytotoxic T Cell Responses," <i>The Journal of Immunology</i> , 164, 5, pp. 2372-2378 (2000).		
m		Van Uden, J. et al., "Immunostimulatory DNA and Applications to Allergic Disease," Journal of Allergy and Clinical Immunology, 104, 5, pp. 903-910 (1999).		
MM		Verthelyi, D. et al., "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs ^{1,2} ," <i>The Journal of Immunology</i> , 166, 4, pp. 2372-2377 (2001).		
MM	Von Hunolstein, C. et al., "Synthetic Oligodeoxynucleotide Containing CpG Motif Induces an Anti-Polysaccharide Type 1-Like Immune Response After Immunization of Mice with Haemophilus Influenzae Type b Conjugate Vaccine," <i>International Immunology</i> , 12, 3, pp. 295-303 (2000).			
M	Voo, K.S. et al., "Cloning of a Mammalian Transcriptional Activator that Binds Unmethylated CpG Motifs and Shares a CXXC Domain with DNA Methyltransferase, Human Trithorax and Methyl-CpG Binding Domain Protein 1," <i>Molecular and Cellular Biology</i> , pp. 2108-2121 (2000).			
MM	Wagner, H., "Bacterial CpG DNA Activates Immune Cells to Signal Infectious Danger," Advances in Immunology, 73, pp. 329-367.			
MM	Walker, P.S. et al., "Immunostimulatory Oligodeoxynucleotides Promote Protective Immunity and Provide Systemic Therapy for Leishmaniasis via IL-12- and IFN-γ-Dependent Mechanisms," <i>Proc. Natl. Acad. Sci. USA</i> , 96, pp. 6970-6975 (1999).			
MM	Weeratna, R.D. et al., "CpG DNA Induces Stronger Immune Responses with Less Toxicity than Other Adjuvants," Vaccine, 18, pp. 1755-1762 (2000).			
	Weiner, G.J., "CpG DNA in Cancer I Springer, Edited by H. Wagner, pp. 1	mmunotherapy", <i>Immunobiology of Bacter</i> 156-170 (2000).	ial CpG-DNA,	

MMManhill 8/31/07/Page 7 of 8

ORMATION DISC	CLOSURE CITATION	OMB No. 0651-0011
	Appln. No. 09/874,991	OEN CE P
James J. MOND et al.	, '	H I
June 7, 2001	Group: _Unassigned /645	V

M		Yamamoto, S. et al., "Oligodeoxyribonucleotides with 5'-ACGT-3' or 5'-TCGA-3' Sequence Induce Production of Interferons," <i>Immunobiology of Bacterial CpG-DNA</i> , Springer, Edited by H. Wagner, pp. 23-39 (2000).
M Mm		Yi, A. et al., "Systemic Induction of IL-6 Transcription Through an Antioxidant-Sensitive Pathway," <i>The Journal of Immunology</i> , 157, 12, pp. 5394-5402 (1996).
		Zhao, Q. et al., "Site of Chemical Modifications in CpG Containing Phosphorothicate Oligodeoxynucleotide Modulates its Immunostimulatory Activity," <i>Bioorganic & Medicinal Chemistry Letters</i> , 9, pp. 3453-3458 (1999).

Atty. Docket No.

Applicant Filing Date

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce